Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Elfabrio

Elfabrio 2 mg/mL concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 7–8

HOS-148147 · Präparat HOS-099842

7  Frequency System organ class Common Uncommon Respiratory, thoracic and bronchospasm* mediastinal disorders sneezing* nasal congestion* dyspnoea* throat irritation* throat tightness Gastrointestinal disorders nausea* gastrooesophageal reflux disease abdominal pain* gastritis diarrhoea dyspepsia vomiting* flatulence Skin and subcutaneous issue rash* hypohidrosis disorders erythema* pruritus* Musculoskeletal and arthralgia connective tissue disorders musculoskeletal pain* Renal and urinary disorders membranoproliferative glomerulonephritis chronic kidney disease proteinuria Reproductive system and nipple pain breast disorders General disorders and asthenia* influenza-like illness administration site conditions chills* infusion site extravasation chest pain* infusion site pain pain* oedema Investigations body temperature increased* urine protein/creatinine ratio increased white blood cells urine positive blood uric acid increased weight increased Injury, poisoning and infusion related reaction* procedural complications Cardiac disorders supraventricular extrasystoles The following preferred terms have been grouped in Table 3: • hypersensitivity includes: drug hypersensitivity • agitation includes: nervousness • abdominal pain includes: abdominal discomfort • rash includes: rash maculo-papular and rash pruritic • musculoskeletal stiffness recorded as musculoskeletal pain includes: myalgia • asthenia includes: malaise and fatigue • chest pain includes: chest discomfort and non-cardiac chest pain • pain includes: pain in extremity • oedema peripheral recorded as oedema

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.